Similar articles

• [Combined chemotherapy of metastatic cancer of the breast].

  Izmaĭlova GE, Letiagin VP, Starikova AB. Izmaĭlova GE, et al. Sov Med. 1988;(4):91-4. Sov Med. 1988. PMID: 3406828 Russian. No abstract available.
• The sound and the fury: an update on the role of high-dose chemotherapy and autologous stem cell salvage for both metastatic and high-risk breast cancer.

  Bar MH. Bar MH. Conn Med. 2000 Jan;64(1):3-6. Conn Med. 2000. PMID: 10697358 Review. No abstract available.
• Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.

  Machiavelli MR, Romero AO, Pérez JE, Lacava JA, Domínguez ME, Rodríguez R, Barbieri MR, Romero Acuña LA, Romero Acuña JM, Langhi MJ, Amato S, Ortiz EH, Vallejo CT, Leone BA. Machiavelli MR, et al. Cancer J Sci Am. 1998 Mar-Apr;4(2):125-31. Cancer J Sci Am. 1998. PMID: 9554929 Clinical Trial.
• Prognostic factors for triple-negative breast cancer patients receiving preoperative systemic chemotherapy.

  Asaga S, Kinoshita T, Hojo T, Suzuki J, Jimbo K, Tsuda H. Asaga S, et al. Clin Breast Cancer. 2013 Feb;13(1):40-6. doi: 10.1016/j.clbc.2012.09.013. Epub 2012 Oct 25. Clin Breast Cancer. 2013. PMID: 23103363
• Adjuvant chemotherapy for breast cancer. National Institutes of Health Consensus Development Conference Statement.

  [No authors listed] [No authors listed] Natl Inst Health Consens Dev Conf Consens Statement. 1985;5(12):5 p.. Natl Inst Health Consens Dev Conf Consens Statement. 1985. PMID: 3908920 Review. No abstract available.